医学
肝细胞癌
成本效益
内科学
重症监护医学
肿瘤科
风险分析(工程)
作者
Neehar D. Parikh,Amit G. Singal,David W. Hutton,Elliot B. Tapper
标识
DOI:10.14309/ajg.0000000000000715
摘要
Accounting for both surveillance-related benefits and harms, US and AFP is more cost-effective for HCC surveillance than US alone or no surveillance in patients with compensated cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI